Revolutionary Blood Test Detects 50 Cancer Types Before Symptoms Appear

2026-02-07 services

Nairobi, 7 February 2026
Hims & Hers has launched access to Galleri, a groundbreaking blood test that screens for over 50 types of cancer from a single sample, including cancers without standard screenings like pancreatic and ovarian. The test works by detecting DNA fragments shed by tumours into the bloodstream, potentially identifying cancers before symptoms develop. Clinical trials showed the test detected 40.4% of cancer cases and over half of early-stage cancers. Grail submitted the test for FDA approval on 29 January 2026, though it remains unapproved. Customers can add the test to existing health plans for £550, representing a £200 discount from the standard price.

How to Access the Galleri Test Through Hims & Hers

The Galleri test became available through Hims & Hers on 3 February 2026, offering customers a streamlined path to advanced cancer screening [2]. To access the test, individuals must first become subscribers to Hims & Hers’ existing laboratory testing service, which costs $350 [1]. The Galleri test can then be added for an additional $700, representing approximately 25% off the standard list price of $949 [1][6]. This pricing structure means customers pay a total of 1050 for both services, saving $250 compared to purchasing Galleri separately [2][6]. The test requires a prescription and eligibility assessment, and it is not available in all 50 US states [2][3]. Customers must answer eligibility questions before adding the test to their existing laboratory plans, with subscriptions becoming bundled and renewing within 365 days [3].

Eligibility Criteria and Important Restrictions

The Galleri test is specifically recommended for adults aged 50 and older who have an elevated risk for cancer [2][4]. Clear restrictions apply to ensure safe and appropriate use: the test is not recommended for individuals who are pregnant, aged 21 years or younger, or currently undergoing active cancer treatment [2]. The test serves as a complement to, not a replacement for, routine cancer screening tests recommended by healthcare providers [2][4]. Importantly, the test has not received FDA approval, though Grail submitted it for formal FDA review on 29 January 2026 [1]. The manufacturer emphasises that false positive and false negative results can occur, and the test does not detect signals for all cancers [2][3]. Some cancers cannot be detected in blood samples, making traditional screening methods still essential for comprehensive cancer detection [3][4].

Clinical Performance and Real-World Results

Clinical trial data from 2025 demonstrates the test’s capabilities and limitations in real-world applications [1]. In a study following nearly 36,000 adults over 50 years old, Galleri detected 40.4% of cancer cases overall [1]. The test showed particular strength in early detection, identifying more than half of Stage 1 and Stage 2 cancers, when treatment outcomes are typically more favourable [1]. For cancers lacking standard screening protocols—such as pancreatic, ovarian, and liver cancers—the test detected approximately three-quarters of cases [1]. However, accuracy concerns remain significant: out of 216 patients flagged by Galleri in the trial, approximately 62% received confirmed cancer diagnoses within a year, whilst 38% were false positives [1]. Dr Eric Topol, director of the Scripps Research Translational Institute, cautioned that many people might struggle to interpret these complex test results appropriately [1].

The Testing Process and Follow-Up Care

The testing process involves a straightforward annual blood draw at any of more than 2,000 Quest Diagnostics locations nationwide [3][4]. Customers can schedule flexible appointments through the Hims & Hers mobile application, with results typically delivered through the same digital platform [3]. Test results come in two clear categories: ‘Cancer Signal Detected’ or ‘No Cancer Signal Detected’ [4]. If a cancer signal appears, Hims & Hers commits to connecting customers with a healthcare provider within 15 hours to review results and discuss next steps [1][4]. Dr Pat Carroll, chief medical officer at Hims & Hers, explained that this rapid response system addresses care gaps that can contribute to delayed diagnoses and unnecessarily complex treatment journeys [1]. However, customers must understand that a positive result requires confirmatory diagnostic testing through established medical procedures such as imaging to confirm actual cancer presence [2][4]. The test serves as a screening tool rather than a diagnostic instrument, with further medical evaluation essential for definitive cancer diagnosis [2][3].

Bronnen

cancer screening blood test